天价救命药有效成分竟为零，假药谋利必须重办

Group 1 - The article discusses two cases related to the purchase of overseas cancer drugs, highlighting the contrast between a compassionate act and a fraudulent scheme [1][2] - The first case involves a man named Lu Yong who imported affordable generic drugs from India to help leukemia patients, resulting in a non-prosecution decision by the authorities, showcasing the humane aspect of the law [1] - In contrast, the second case involves a man named Mao who sold counterfeit cancer drugs, specifically a generic version of the patented drug Anlotinib, which contained no effective ingredients and was priced around 1500 yuan per box [1] Group 2 - The counterfeit drugs pose significant dangers, draining patients' savings, delaying treatment, and undermining pharmaceutical intellectual property rights, which could stifle innovation in the industry [1][2] - The article emphasizes the need for improved medical insurance coverage for cancer drugs, urging relevant departments to accelerate the optimization of insurance policies and provide clear information to patients about legitimate purchasing channels [2] - Protecting pharmaceutical intellectual property is crucial, as the development of original cancer drugs like Anlotinib requires substantial time and financial investment, and its recognition with a national patent award exemplifies the importance of safeguarding innovation [2]